Commenting on MacroGenics' Phase 3 SOPHIA trial, Credit Suisse analyst Michael Morabito says that physician experts with whom he has been consulting were hoping for a benefit of at least 2 months compared to Herceptin, which they would consider practice changing in this third-line setting of patients who progressed on Herceptin/Perjeta/Kadcyla. With the net benefit for margetuximab coming in at only 0.9 months, the analyst would expect the shares could see increased pressure on this data. He reiterates an Outperform rating and $29 price target on the shares.